Reginald F. Frye

6.7k total citations
160 papers, 5.2k citations indexed

About

Reginald F. Frye is a scholar working on Pharmacology, Pharmacology and Molecular Biology. According to data from OpenAlex, Reginald F. Frye has authored 160 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Pharmacology, 44 papers in Pharmacology and 36 papers in Molecular Biology. Recurrent topics in Reginald F. Frye's work include Pharmacogenetics and Drug Metabolism (64 papers), Antibiotics Pharmacokinetics and Efficacy (29 papers) and Drug Transport and Resistance Mechanisms (23 papers). Reginald F. Frye is often cited by papers focused on Pharmacogenetics and Drug Metabolism (64 papers), Antibiotics Pharmacokinetics and Efficacy (29 papers) and Drug Transport and Resistance Mechanisms (23 papers). Reginald F. Frye collaborates with scholars based in United States, Saudi Arabia and Austria. Reginald F. Frye's co-authors include Gary R. Matzke, Robert A. Branch, Mohamed‐Eslam F. Mohamed, Patricia D. Kroboth, Tanya J. Fabian, Amy L. Pittenger, Matthew Hruska, Adedayo Adedoyin, Thomas D. Nolin and Khalid M. Alkharfy and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Kidney International.

In The Last Decade

Reginald F. Frye

158 papers receiving 5.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reginald F. Frye United States 40 1.8k 1.0k 924 924 742 160 5.2k
Christian Funck‐Brentano France 47 1.6k 0.9× 1.3k 1.3× 926 1.0× 1.3k 1.4× 567 0.8× 205 7.7k
J. Feely Ireland 51 830 0.5× 583 0.6× 660 0.7× 564 0.6× 1.1k 1.5× 255 7.8k
D. Craig Brater United States 50 1.2k 0.6× 1.2k 1.2× 2.0k 2.2× 604 0.7× 631 0.9× 197 8.4k
Garry G. Graham Australia 31 910 0.5× 1.3k 1.3× 977 1.1× 678 0.7× 670 0.9× 115 5.0k
Laurent Becquemont France 39 1.8k 1.0× 791 0.8× 958 1.0× 1.3k 1.5× 644 0.9× 171 5.9k
Steffen Bauer Germany 37 2.1k 1.2× 900 0.9× 762 0.8× 1.2k 1.3× 349 0.5× 85 5.0k
Stephan Krähenbühl Switzerland 50 1.5k 0.8× 3.0k 3.0× 617 0.7× 1.4k 1.5× 756 1.0× 227 8.6k
In‐Jin Jang South Korea 40 1.2k 0.7× 1.5k 1.5× 808 0.9× 1.6k 1.7× 571 0.8× 306 5.9k
AM Breckenridge United Kingdom 47 1.7k 1.0× 564 0.6× 862 0.9× 779 0.8× 668 0.9× 157 5.8k
Shiew‐Mei Huang United States 47 2.4k 1.3× 1.1k 1.1× 712 0.8× 1.8k 2.0× 250 0.3× 147 5.7k

Countries citing papers authored by Reginald F. Frye

Since Specialization
Citations

This map shows the geographic impact of Reginald F. Frye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reginald F. Frye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reginald F. Frye more than expected).

Fields of papers citing papers by Reginald F. Frye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reginald F. Frye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reginald F. Frye. The network helps show where Reginald F. Frye may publish in the future.

Co-authorship network of co-authors of Reginald F. Frye

This figure shows the co-authorship network connecting the top 25 collaborators of Reginald F. Frye. A scholar is included among the top collaborators of Reginald F. Frye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reginald F. Frye. Reginald F. Frye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bril, Fernando, Srilaxmi Kalavalapalli, Romina Lomonaco, et al.. (2024). Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants. JHEP Reports. 6(7). 101092–101092. 17 indexed citations
2.
Voils, Stacy A., et al.. (2020). Intensive Care Unit Delirium in Surgical Patients Is Associated with Upregulation in Tryptophan Metabolism. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 40(6). 500–506. 12 indexed citations
3.
Kalavalapalli, Srilaxmi, Fernando Bril, Jeremy P. Koelmel, et al.. (2018). Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis. American Journal of Physiology-Endocrinology and Metabolism. 315(2). E163–E173. 55 indexed citations
4.
Kawaguchi‐Suzuki, Marina, Fernando Bril, Srilaxmi Kalavalapalli, Kenneth Cusi, & Reginald F. Frye. (2017). Concentration‐dependent response to pioglitazone in nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 46(1). 56–61. 22 indexed citations
5.
Shahin, Mohamed H., Yan Gong, Caitrin W. McDonough, et al.. (2016). Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics. 12(8). 10 indexed citations
6.
Shahin, Mohamed H., Yan Gong, Caitrin W. McDonough, et al.. (2016). A Genetic Response Score for Hydrochlorothiazide Use. Hypertension. 68(3). 621–629. 21 indexed citations
7.
Rotroff, Daniel M., Hongjie Zhu, Alison A. Motsinger‐Reif, et al.. (2015). Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes. CPT Pharmacometrics & Systems Pharmacology. 4(11). 669–679. 30 indexed citations
8.
Ardjomand-Woelkart, Karin, Manfred Kollroser, Christoph Magnes, et al.. (2011). Absolute/Relative Bioavailability and Metabolism of Dodeca-2E,4E,8Z,10E/Z-Tetraenoic Acid Isobutylamides (Tetraenes) after Intravenous and Oral Single Doses to Rats. Planta Medica. 77(16). 1794–1799. 7 indexed citations
9.
Mohamed, Mohamed‐Eslam F., et al.. (2008). Determination of mycophenolic acid glucuronide in microsomal incubations using high performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B. 870(2). 251–254. 9 indexed citations
10.
Harbrecht, Brian G., Reginald F. Frye, Mazen S. Zenati, Robert A. Branch, & Andrew B. Peitzman. (2005). Cytochrome P-450 activity is differentially altered in severely injured patients. Critical Care Medicine. 33(3). 541–546. 29 indexed citations
11.
Komoroski, Bernard J., Shimin Zhang, Hongbo Cai, et al.. (2004). INDUCTION AND INHIBITION OF CYTOCHROMES P450 BY THE ST. JOHN’S WORT CONSTITUENT HYPERFORIN IN HUMAN HEPATOCYTE CULTURES. Drug Metabolism and Disposition. 32(5). 512–518. 143 indexed citations
12.
Nolin, Thomas D., Reginald F. Frye, & Gary R. Matzke. (2003). Hepatic drug metabolism and transport in patients with kidney disease. American Journal of Kidney Diseases. 42(5). 906–925. 83 indexed citations
13.
Hutzler, J. Matthew, Reginald F. Frye, Kenneth R. Korzekwa, et al.. (2001). Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone. European Journal of Pharmaceutical Sciences. 14(1). 47–52. 38 indexed citations
14.
Kroboth, Patricia D., et al.. (1999). DHEA and DHEA‐S: A Review. The Journal of Clinical Pharmacology. 39(4). 327–348. 414 indexed citations
15.
Frye, Reginald F.. (1998). Using preventive care to decrease hospital admissions of pediatric patients.. PubMed. 16(9). 16–7. 1 indexed citations
16.
Frye, Reginald F., et al.. (1997). Drug Administration in Patients with Renal Insufficiency Minimising Renal and Extrarenal Toxicity. Drug Safety. 16(3). 205–231. 69 indexed citations
17.
Frye, Reginald F. & Robert A. Branch. (1996). Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection. Journal of Chromatography B Biomedical Sciences and Applications. 677(1). 178–182. 20 indexed citations
18.
Stiff, Dwight D., Reginald F. Frye, & Robert A. Branch. (1993). Sensitive high-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in plasma. Journal of Chromatography B Biomedical Sciences and Applications. 613(1). 127–131. 17 indexed citations
19.
Frye, Reginald F., et al.. (1992). Pharmacodynamic modeling of erythropoietin therapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 12(6). 504.
20.
Frye, Reginald F., et al.. (1992). The influence of type i and type ii diabetes mellitus on antipyrine disposition. Clinical Pharmacology & Therapeutics. 51(2). 134. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian Funck‐Brentano Breakdown of academic impact, for papers by J. Feely Breakdown of academic impact, for papers by D. Craig Brater Breakdown of academic impact, for papers by Garry G. Graham Breakdown of academic impact, for papers by Laurent Becquemont Breakdown of academic impact, for papers by Steffen Bauer Breakdown of academic impact, for papers by Stephan Krähenbühl Breakdown of academic impact, for papers by In‐Jin Jang Breakdown of academic impact, for papers by AM Breckenridge Breakdown of academic impact, for papers by Shiew‐Mei Huang
Rankless by CCL
2026